Transparency and diversity in cystic fibrosis research – Authors' reply

Karen S. McCoy; Harry Heijerman; Jennifer L. Taylor-Cousar; David Waltz; Patrick R. Sosnay; Bonnie W. Ramsey; Steven Rowe; John Welter

doi:10.1016/S0140-6736(20)30897-7

Transparency and diversity in cystic fibrosis research – Authors' reply

Karen S. McCoy, Harry Heijerman, Jennifer L. Taylor-Cousar, David Waltz, Patrick R. Sosnay, Bonnie W. Ramsey, Steven Rowe, John Welter

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	602
Number of pages	1
Journal	The Lancet
Volume	396
Issue number	10251
DOIs	https://doi.org/10.1016/S0140-6736(20)30897-7
State	Published - Aug 29 2020
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(20)30897-7

Cite this

@article{89badaea43c44e08acc4edce7a9203a6,

title = "Transparency and diversity in cystic fibrosis research – Authors' reply",

author = "McCoy, {Karen S.} and Harry Heijerman and Taylor-Cousar, {Jennifer L.} and David Waltz and Sosnay, {Patrick R.} and Ramsey, {Bonnie W.} and Steven Rowe and John Welter",

note = "Funding Information: KSM reports research grants from AbbVie, Alcresta, Allergan, Corbus, Novoteris, Gilead, Janssen, Laurent, Novoteris, Proteostasis, Savara, Translate Bio, Vertex, and Vivus for which her institution (Nationwide Children's Hospital, Ohio State University, Columbus, OH, USA) received payment; and non-financial support from Chiesi. BWR reports research grants from Vertex, for which her institution (Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, USA) received payment; non-financial support from Novartis; and honoraria from Vertex. SR reports research grants from AstraZeneca, Bayer, Celtaxys, Eloxx, Forest Research Institute, Galapagos (AbbVie), N30 (Nivalis), Novartis, PTC Therapeutics, Synedgen (Synspira), Vertex Pharmaceuticals, Vivus (Janssen), and Actelion (Johnson & Johnson), for which his institution (University of Alabama at Birmingham, Birmingham, AL, USA) received payment; consulting fees from Bayer, Celtaxys, Novartis, Renovion, Synedgen (Synspira), and Vertex Pharmaceuticals; fees for advisory board participation for Vertex Pharmaceuticals; and honoraria from Genentech and Boeringher Ingelheim. JW reports grants from AbbVie, Allergan, Concert, Janssen, Proteostasis, and Vertex Pharmaceuticals, for which his institution (New York Medical College, New York, NY, USA) received payment; and non-financial support from Vertex Pharmaceuticals.",

year = "2020",

month = aug,

day = "29",

doi = "10.1016/S0140-6736(20)30897-7",

language = "English (US)",

volume = "396",

pages = "602",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10251",

}

TY - JOUR

T1 - Transparency and diversity in cystic fibrosis research – Authors' reply

AU - McCoy, Karen S.

AU - Heijerman, Harry

AU - Taylor-Cousar, Jennifer L.

AU - Waltz, David

AU - Sosnay, Patrick R.

AU - Ramsey, Bonnie W.

AU - Rowe, Steven

AU - Welter, John

N1 - Funding Information: KSM reports research grants from AbbVie, Alcresta, Allergan, Corbus, Novoteris, Gilead, Janssen, Laurent, Novoteris, Proteostasis, Savara, Translate Bio, Vertex, and Vivus for which her institution (Nationwide Children's Hospital, Ohio State University, Columbus, OH, USA) received payment; and non-financial support from Chiesi. BWR reports research grants from Vertex, for which her institution (Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, USA) received payment; non-financial support from Novartis; and honoraria from Vertex. SR reports research grants from AstraZeneca, Bayer, Celtaxys, Eloxx, Forest Research Institute, Galapagos (AbbVie), N30 (Nivalis), Novartis, PTC Therapeutics, Synedgen (Synspira), Vertex Pharmaceuticals, Vivus (Janssen), and Actelion (Johnson & Johnson), for which his institution (University of Alabama at Birmingham, Birmingham, AL, USA) received payment; consulting fees from Bayer, Celtaxys, Novartis, Renovion, Synedgen (Synspira), and Vertex Pharmaceuticals; fees for advisory board participation for Vertex Pharmaceuticals; and honoraria from Genentech and Boeringher Ingelheim. JW reports grants from AbbVie, Allergan, Concert, Janssen, Proteostasis, and Vertex Pharmaceuticals, for which his institution (New York Medical College, New York, NY, USA) received payment; and non-financial support from Vertex Pharmaceuticals.

PY - 2020/8/29

Y1 - 2020/8/29

UR - http://www.scopus.com/inward/record.url?scp=85089795116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089795116&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(20)30897-7

DO - 10.1016/S0140-6736(20)30897-7

M3 - Letter

C2 - 32861305

AN - SCOPUS:85089795116

SN - 0140-6736

VL - 396

SP - 602

JO - The Lancet

JF - The Lancet

IS - 10251

ER -

Transparency and diversity in cystic fibrosis research – Authors' reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this